Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

April 10, 2006 10:19 ET

Miraculins Signs Agreement with Duke University Medical Center for Prostate Cancer Diagnostic Project

WINNIPEG, MANITOBA--(CCNMatthews - April 10, 2006) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of products for select cancers, is pleased to announce an agreement with Duke University Medical Center ("DUMC") to further the development of Miraculins' prostate cancer diagnostic project. Under the terms of the agreement, Miraculins will combine its internal research expertise with the considerable research capabilities and patient network of DUMC.

The Company's collaboration with DUMC, under the direction of Lead Investigator Dr. Judd W. Moul, Professor and the Chief of Urological Surgery at DUMC, will allow for the refinement and confirmation of results from the discovery phase of Miraculins' Prostate Cancer Diagnostic Project. These results were recently presented at the American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics, and included Company developed algorithms and several biomarkers on which the Company has patent protection.

DUMC and Miraculins share a common goal of improving the global capability to diagnose and detect cancer, as an important part of the strategy to ultimately treat the disease.

"There is a critical need for new molecular biomarkers to help us to better care for our patients with cancer. For prostate cancer in particular, the problem is magnified due to the widely varying behavior of these cancers in individual men", stated Dr. Moul, Lead Investigator on the Study.

"It is an important part of Miraculins' strategy to work with the best institutions," stated Dr. Jim Charlton, President of Miraculins Inc. "This agreement with a world class institution such as Duke University Medical Center is integral to our rigorous scientific validation process."

The study has been designed to facilitate completion of the validation phase for the most promising markers and algorithms developed by Miraculins. This is a significant milestone that must be completed on the road to commercializing a relevant diagnostic test.

The agreement is also an important part of Miraculins commitment to establishing a strong network of clinical research institutions to support its goal of building a pipeline of cancer markers for further development.

About Dr. Judd W. Moul, M.D., F.A.C.S.

Dr. Moul is a Professor at Duke University and the Chief of Urological Surgery at the Duke University Medical Center. His research is primarily focused on clinical trials in prostate disease, and he is a noted authority on biochemical recurrence of prostate cancer, multi-disciplinary management of prostate cancer and nerve-sparing radical prostatectomy.

Dr. Moul, is also the former director of the Center for Prostate Disease Research, a Congressionally mandated, Department of Defense research program, and has been nationally recognized for his creation of a U.S. military-based prostate disease research database that houses information on tens of thousands of prostate cancer patients.

Dr. Moul is on the editorial board of several medical journals, including Oncology, Journal of Urology, Urology, and the periodical Oncology News International. He is also co-editor of the journal, Prostate Cancer and Prostatic Diseases, and is medical editor for Family Urology, a patient education magazine published by the American Foundation for Urologic Disease. Dr. Moul has authored or co-authored more than 275 scientific manuscripts and book chapters, including articles in the New England Journal of Medicine and the Journal of the American Medical Association.

About Duke University Medical Center

Duke University Medical Center -- the centerpiece of Duke's wide-ranging medical programs -- is located on the Duke University campus in Durham, North Carolina. The youngest of the nation's leading medical centers, it has grown in just the past three decades from a hospital and single research building into one of the country's largest clinical and biomedical research institutions.

Duke today operates one of the country's largest clinical and biomedical research enterprises, and works to translate advances in medical knowledge into improved patient care. Its educational programs -- training hundreds of new physicians, nurses, and other health professionals each year -- are regularly recognized among the America's very finest.

About Miraculins Inc.

Miraculins is a biotechnology company focused on commercializing products for the diagnosis and treatment of select cancers. The Company's lead product focuses on improving the diagnosis of prostate cancer.

Prostate cancer is responsible for greater than 240,000 new diagnoses in North America each year. The current screening standard for prostate cancer, PSA, is ineffective at reliably distinguishing between non-life threatening prostate conditions and critical prostate cancer. In spite of this fact, there are greater than 25 million PSA tests performed annually in the United States alone, resulting in one million prostate biopsy procedures. An estimated 75% of these procedures are unnecessary and could be avoided if an improved diagnostic technique was available.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information